Nian-Qiu Shi is an assistant professor at the School of Pharmacy, Jilin Medical University.He obtained his master's degree (2006) of Pharmaceutics from Shenyang Pharmaceutical University and PhD (2012) in Pharmaceutics from Peking University. He was a senior scientist at State Key Laboratory of Drug Delivery Technology and Pharmacokinetics in Tianjin Institute of Pharmaceutical Research during 2012-2013. He joined the Department of Pharmaceutics at Jilin Medical University as High-level personnel of special support program in 2013 and is a member currently. He completed postdoctoral training (2014-2016) in the Jilin University. Dr. Shi has honored as Outstanding Young Scientists of Jilin city in 2014. He is serving as many referees or reviewer of several journals including Mol Pharmaceutics (IF=4.787), Export Opinion On Drug Delivery (IF=4.116), Critical Rev in Therapeutic Drug Carrier Systems (IF=3.174), Powder Technology (IF=2.269), Drug Dev Ind Pharm (IF=2.006), Journal of Microencapsulation (IF=1.878), Pharmaceutical Development Technology (IF=1.335), Asian Journal of Pharmaceutical Sciences, Acta Pharmaceutica Sinica, Chinese Pharmaceutical Journal, Chinese Journal of Pharmaceuticals and Journal of Shenyang Pharmaceutical University. He is also some members of the Editorial Advisory Board of some journals. He has published more than 20 research papers and reviews.
Nian-Qiu Shi Research Interests are Multifunctional nanocarriers or macromolecules have many advantages for diseases treatments. Dr Shi employs diverse targeting delivery systems including conjugate, liposomes and micelles to deliver anticancer drug or gene for tumor therapy. In this process, Dr Shi unitizes stimuli-responsive strategies (e.g. enzyme-responsive) to obtain the targeting therapy of tumor. Cell-penetrating peptides (CPPs) are also adopted to cross cellular barriers. Internalization mechanisms of CPPs or CPP-cargoes are also focused by Dr Shi. According Biopharmaceutics Classification System (BCS) theory, BCS II drugs have low solubility and high permeability, frequently resulting low dissolution or bioavailability. Dr Shi also adopts amorphous technology to improve the solubility, dissolution and bioavailability of model active pharmaceutical ingredients (APIs) belonging to BCS II by the usage of polymers. Dr Shi focuses on the influence of used polymers on dissolution and crystallization process, and explore the inherent principle and association. Other technologies and application in industrial pharmaceutics are also explored.